Medical Laboratory Technology Department, College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.
Central Blood Bank and Regional Laboratory, General Directorate of Health Affairs, Ministry of Health, Madinah, Saudi Arabia.
Viral Immunol. 2022 Mar;35(2):122-128. doi: 10.1089/vim.2021.0108. Epub 2021 Nov 5.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19), which has affected hundreds of millions of people globally. The development of safe and effective vaccines represents an urgent demand. A total of 136 participants were recruited in this study, including 75 men and 61 women. The participants were divided into two groups: those who were virus naïve (never infected) and those who had recovered from COVID-19. Each group included individuals who received either the Pfizer-BioNTech BNT162b2 mRNA or the Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine. Enzyme-linked immunosorbent assay (ELISA) was used to measure anti-S IgG antibody concentrations in sequential serum samples obtained before vaccine administration, after the first vaccine dose, and after the second vaccine dose. We compared the antibody responses of individuals with confirmed prior COVID-19 infection with those of individuals without prior evidence of infection. All participants who were previously infected with SARS-CoV-2 who received one dose of either the Pfizer-BioNTech BNT162b2 mRNA or the Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine showed significant anti-S IgG antibody levels. No sex-related differences were observed when we compared antibody levels between men and women. In infection-naïve participants ≥60 years, a second vaccine dose was necessary to achieve higher levels of antibody when comparing the IgG antibody levels after receiving the first and second dose.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染会引起 2019 年冠状病毒病（COVID-19），该病已在全球范围内影响了数亿人。开发安全有效的疫苗是当务之急。本研究共招募了 136 名参与者，其中 75 名男性和 61 名女性。参与者被分为两组：从未感染过病毒的组和从 COVID-19 中康复的组。每组均包括接受辉瑞-生物科技 BNT162b2 mRNA 或牛津-阿斯利康 ChAdOx1 COVID-19 疫苗的个体。酶联免疫吸附试验（ELISA）用于测量在接种疫苗前、第一剂疫苗后和第二剂疫苗后获得的连续血清样本中的抗-S IgG 抗体浓度。我们比较了有明确既往 COVID-19 感染史的个体与无既往感染证据的个体的抗体反应。所有先前感染过 SARS-CoV-2 的参与者，无论接受辉瑞-生物科技 BNT162b2 mRNA 还是牛津-阿斯利康 ChAdOx1 COVID-19 疫苗一剂，均显示出显著的抗-S IgG 抗体水平。在比较男性和女性的抗体水平时，未观察到与性别相关的差异。在≥60 岁的无感染史参与者中，与接受第一和第二剂后的 IgG 抗体水平相比，需要第二剂疫苗才能达到更高的抗体水平。
